Will Gleevec, Sprycel researchers get a call from Stockholm?

Scientists who worked on the targeted leukemia drugs Gleevec and Sprycel may be in line for the Nobel Prize this year, a prize-prediction expert says. The drugs, sold by Novartis ($NVS) and Bristol-Myers Squibb ($BMY) respectively, represent "a fundamental discovery in medicine...with a fantastic result which is often referred to in terms like 'magic bullet'," analyst David Pendlebury tells Reuters. "It has really given a new paradigm for the treatment of cancer." Report

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…